Targeting cancer gene mutations has been changing the way non-small cell lung cancer ( NSCLC ) is treated. As scientists learn more about the genetic makeup of tumors, more personalized therapy has become available.

After the initial therapy for esophageal cancer fails, patients don’t have many choices. A recent study finds that a second-line therapy could be coming online.